Stock Events

Stock Events

Moleculin Biotech 

€0
76
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-14.64
-9.01
-3.38
2.25
Expected EPS
-1.43519024572
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-40.99MNet Income

Analyst Ratings

$16.69Average Price Target
The highest estimate is 16.69.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MOL0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Moleculin, including cancer, making it a direct competitor.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for cancer, which competes with Moleculin's cancer drug development efforts.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines for cancer, directly competing with Moleculin's oncology focus.
Merck
MRK
Mkt Cap214.76B
Merck operates in the pharmaceutical industry with a strong emphasis on cancer drugs, competing with Moleculin's product pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company with a broad range of drugs, including cancer treatments that compete with Moleculin's developments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a healthcare company that offers treatments for a variety of conditions, including cancer, making it a competitor to Moleculin.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on oncology, directly competing with Moleculin's focus areas.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly is a global healthcare leader that develops drugs for cancer among other diseases, positioning it as a competitor to Moleculin.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a significant focus on oncology, competing with Moleculin.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovative medicines and therapeutic advancements, including in oncology, making it a competitor to Moleculin.

About

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Show more...
CEO
ISIN
US60855D4088
WKN
000A41SET

Listings

F
DE
MOL0.F
LSE
GB
0K2H.LSE
BOATS
BOATS
MBRX.BOATS
XNAS
US
MBRX

0 Comments

Share your thoughts

FAQ

What is Moleculin Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Moleculin Biotech stocks are traded under the ticker MOL0.F.
When is the next Moleculin Biotech earnings date?▼
Moleculin Biotech is going to release the next earnings report on May 07, 2026.
What were Moleculin Biotech earnings last quarter?▼
MOL0.F earnings for the last quarter are 2.25 EUR per share, whereas the estimation was -5.28 EUR resulting in a +142.69% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Moleculin Biotech revenue for the last year?▼
Moleculin Biotech revenue for the last year amounts to 0 EUR.
What is Moleculin Biotech net income for the last year?▼
MOL0.F net income for the last year is -40.99M EUR.
When did Moleculin Biotech complete a stock split?▼
The last stock split for Moleculin Biotech was on December 01, 2025 with a ratio of 1:25.